Navigation Links
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
Date:3/14/2011

CRANBURY, N.J., March 14, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

"We are so pleased that Cornerstone has received a report from NCI indicating that Emulsiphan appears to be safe and capable as a drug delivery solution for anticancer agents," said Dr. Robert Shorr, CEO of Cornerstone Pharmaceuticals, Inc.

"Combining anticancer agents with a targeted drug delivery technology, such as Emulsiphan, could greatly improve patient outcomes. We look forward to the next phase of preclinical study in our ongoing collaboration with NCI."

The preclinical study, which looked at the safety of azide drug-loaded Emulsiphan nano emulsions, is the first step in a collaboration between Cornerstone and NCI to apply Cornerstone's drug delivery platform to a class of novel chemotherapy agents developed by Dr. Yossef Raviv in the laboratory of the renowned biologist Dr. Robert Blumenthal at NCI's Center for Cancer Research Nanobiology Program.

Selective drug delivery remains a formidable challenge in the successful treatment of cancer. Often, just a small percentage of the active ingredients in chemotherapies administered to treat tumors ever reach the desired target within cancer cells and considerable amounts of drug spread to healthy cells and tissue.

Emulsiphan is a novel, cancer selective drug-delivery nanotechnology that aims to deposit cancer-fighting drugs directly into cancer cells--not just the tumor mass--by focusing on the distinct metabolism of these cells.  The nanotechnology is designed to maximize drug concentration into tumor cells, thereby enhancing the anti-cancer compoun
'/>"/>

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
2. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
3. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
9. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
10. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
11. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $453.1 million, a 9 percent increase ... 17 percent increase on a constant currency basis).  Net ... June 30, 2014.  Diluted earnings per share for the ... 30, 2014.  The results for the ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... Back packs ... in a school, however, back packs can wreck havoc on a kid's spine. With ... their supplies to and from school. Make sure you are aware of how to ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Tina Wilcoxson, ... Champions.” , Wilcoxson was given that honor by the National Retail Federation, the largest ... industry. Wilcoxson was one of three Maine business owners to be named as such. ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced ... donation to kick off the campaign for healing and Well-Being. , BeverlyD has helped ... line of raw, organic hair care products, as well as her book, Hair Now!— ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... found in the River Cam in Cambridge, famous as ... lazy summer days, could become the next generation of ... 2007) at the Society for General Microbiologys 161st Meeting ... 3-6 September 2007. , With antibiotics now over-prescribed for ...
... of schizophrenia, INDIANAPOLIS, Sept. 2 An investigational,phase ... that for the first time in humans a drug ... has antipsychotic activity. The study,was sponsored by Eli Lilly ... study - a randomized, double-blind, placebo-controlled clinical,trial - patients ...
... known as a troublemaker for triggering the itch and inflammation ... the flare-ups, researchers from Stanford University School of Medicine have ... the online version of Nature Immunology, reveal that, in mice, ... exposure or from poison oak. , "These reactions are much ...
... Chinas efforts to control population growth in the present ... the future. , This prediction comes from a Saint ... year in China studying its geriatric policies and practices. ... internal medicine in the division of geriatric medicine at ...
... A nanoparticle drug delivery system designed for brain tumour ... novel cell culture model devised by scientists at The ... Schools of Pharmacy, Biomedical Sciences and Human Development, will ... Biology and Medicine. , Therapy for brain cancers is ...
... an important drug used in the treatment of malignant melanoma ... activates immune-system cells to fight the disease. , The ... microscopic tumor cells that may remain in the body following ... for this purpose. , Researchers say that these findings ...
Cached Medicine News:Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 2Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 3Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 4Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 5Health News:Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 6Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 2Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Melanoma drug revs immune cells but cancer cells ignore it 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: